Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels.
William A E ParkerChristian SchulteTemo BarwariFladia PhoenixSam M PearsonManuel MayrPeter J GrantRobert F StoreyRamzi A AjjanPublished in: Cardiovascular diabetology (2020)
Prasugrel monotherapy in T2DM provided potent platelet inhibition and reduced levels of a number of platelet-associated miRNAs. miR-197 is a potential marker of cardiovascular disease in this population. Clinical outcome studies investigating prasugrel monotherapy are warranted in individuals with T2DM. Trial registration EudraCT, 2009-011907-22. Registered 15 March 2010, https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011907-22/GB.
Keyphrases
- percutaneous coronary intervention
- study protocol
- open label
- combination therapy
- phase iii
- antiplatelet therapy
- cardiovascular disease
- phase ii
- acute coronary syndrome
- clinical trial
- randomized controlled trial
- coronary artery disease
- cell proliferation
- long non coding rna
- low dose
- cardiovascular events
- type diabetes
- atrial fibrillation
- anti inflammatory
- placebo controlled
- double blind
- risk assessment
- case control